Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
Launched by MIN ZHAO,MD · Mar 20, 2025
Trial Information
Current as of April 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new imaging technique called targeted α-synuclein PET imaging to help diagnose Multiple System Atrophy (MSA), a rare brain disorder that affects movement and coordination. The study aims to understand how much of a protein called α-synuclein is present in patients with different types of MSA and how this information can help doctors better diagnose the condition, assess its severity, and predict its progression.
To participate in this trial, you need to be at least 35 years old and have a confirmed diagnosis of MSA based on specific medical guidelines. The study is open to everyone, regardless of gender. Participants will undergo imaging tests to capture important information about their condition. However, if you are pregnant, breastfeeding, or have other significant neurological issues, you may not be eligible to join. If you decide to participate, you'll need to provide your consent and be willing to complete the required tests. This trial is currently recruiting participants, so it's a great opportunity to contribute to research that could improve the understanding and management of MSA.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\> 35 years old, gender is not limited;
- • Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
- • all patients had been ruled out of polyQ disease by genetic testing;
- • Voluntarily participate in this study and sign the informed consent form.
- Exclusion Criteria:
- • pregnancy or breastfeeding;
- • contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
- • previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
- • History of alcohol or drug abuse
About Min Zhao,Md
Dr. Min Zhao, MD, is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With expertise in [specific field or specialty, if applicable], Dr. Zhao leads innovative studies designed to explore new therapies and treatment modalities. Leveraging a robust network of clinical sites and a patient-centered approach, Dr. Zhao ensures the highest standards of scientific rigor and ethical conduct in all trials. His collaborative spirit and focus on data integrity contribute to the development of effective healthcare solutions that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hunan, Changsha, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported